If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Trulicity ® (dulaglutide) injection
0.75 mg/0.5 mL, 1.5 mg/0.5 mL, 3mg/0.5mL, 4.5mg/0.5mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Have hypersensitivity reactions been reported with Trulicity® (dulaglutide)?
Serious hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported with dulaglutide.
See important safety information, including boxed warning, in the attached prescribing information.
Dulaglutide and Hypersensitivity
Serious hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported with dulaglutide.1
If a hypersensitivity reaction occurs, discontinue dulaglutide; treat promptly per standard of care, and monitor until signs and symptoms resolve.1
Dulaglutide is contraindicated in patients with a previous serious hypersensitivity reaction to dulaglutide or to any of the components of dulaglutide.1
Anaphylaxis and angioedema have been reported with other glucagon-like peptide-1 receptor agonists (GLP-1 RAs).1
Use caution in a patient with a history of angioedema or anaphylaxis with another GLP-1 RA because it is unknown whether such patients will be predisposed to anaphylaxis with dulaglutide.1
Clinical Study Experience
Systemic hypersensitivity adverse reactions, sometimes severe, occurred in 0.5% of adult patients on dulaglutide in clinical studies and included
- severe urticaria
- systemic rash
- facial edema, and
- lip swelling.1
Enclosed Prescribing Information
Reference
1Trulicity [package insert]. Indianapolis, IN: Eli Lilly and Company; 2024.
Date of Last Review: April 03, 2025